InterobServer AgreeMent in Pd-l1 evaLuatIoN on cytoloGical samples—SAMPLING project: A multi-institutional, international study

IF 2.6 3区 医学 Q3 ONCOLOGY
Gennaro Acanfora MD, Antonino Iaccarino CT, PhD, Bruna Cerbelli MD, PhD, Claudio Di Cristofano MD, Claudio Bellevicine MD, PhD, Massimo Barberis MD, Emanuela Bonoldi MD, Lukas Bubendorf MD, Andreas Calaminus MD, MIAC, Severo Campione MD, PhD, Sule Canberk MD, Alberto Cavazza MD, Giorgio Cazzaniga MD, Obinna Chijioke MD, Eduardo Clery MD, Albino Eccher MD, Marianne Engels MD, Fiac, Vincenzo Fiorentino MD, Paolo Graziano MD, Izidor Kern MD, Ivana Kholova MD, PhD, MIAC, Jari Laatta MD, Tania Labiano MD, Martina Leopizzi CT, PhD, Maria D. Lozano MD, Rita Luis MD, Elisabetta Maffei MD, Alessandro Marando MD, Maurizio Martini MD, PhD, Elisabetta Merenda MD, Marco Montella MD, PhD, Allan Argueta Morales MD, Michiya Nishino MD, PhD, Fabio Pagni MD, Paul Hofman MD, PhD, Angelina Pernazza MD, PhD, Sinchita Roy-Chowdhuri MD, PhD, Mauro Saieg MD, PhD, MIAC, Spasenija Savic Prince MD, Momin T. Siddiqui MD, Tajana Stoos-Veic MD, PhD, Margareta Strojan Fležar MD, PhD, MIAC, Dinka Sundov MD, PhD, Paul VanderLaan MD, PhD, Danijela Vrdoljak-Mozetič MD, PhD, Pio Zeppa MD, PhD, Giancarlo Troncone MD, PhD, Elena Vigliar MD, PhD
{"title":"InterobServer AgreeMent in Pd-l1 evaLuatIoN on cytoloGical samples—SAMPLING project: A multi-institutional, international study","authors":"Gennaro Acanfora MD,&nbsp;Antonino Iaccarino CT, PhD,&nbsp;Bruna Cerbelli MD, PhD,&nbsp;Claudio Di Cristofano MD,&nbsp;Claudio Bellevicine MD, PhD,&nbsp;Massimo Barberis MD,&nbsp;Emanuela Bonoldi MD,&nbsp;Lukas Bubendorf MD,&nbsp;Andreas Calaminus MD, MIAC,&nbsp;Severo Campione MD, PhD,&nbsp;Sule Canberk MD,&nbsp;Alberto Cavazza MD,&nbsp;Giorgio Cazzaniga MD,&nbsp;Obinna Chijioke MD,&nbsp;Eduardo Clery MD,&nbsp;Albino Eccher MD,&nbsp;Marianne Engels MD, Fiac,&nbsp;Vincenzo Fiorentino MD,&nbsp;Paolo Graziano MD,&nbsp;Izidor Kern MD,&nbsp;Ivana Kholova MD, PhD, MIAC,&nbsp;Jari Laatta MD,&nbsp;Tania Labiano MD,&nbsp;Martina Leopizzi CT, PhD,&nbsp;Maria D. Lozano MD,&nbsp;Rita Luis MD,&nbsp;Elisabetta Maffei MD,&nbsp;Alessandro Marando MD,&nbsp;Maurizio Martini MD, PhD,&nbsp;Elisabetta Merenda MD,&nbsp;Marco Montella MD, PhD,&nbsp;Allan Argueta Morales MD,&nbsp;Michiya Nishino MD, PhD,&nbsp;Fabio Pagni MD,&nbsp;Paul Hofman MD, PhD,&nbsp;Angelina Pernazza MD, PhD,&nbsp;Sinchita Roy-Chowdhuri MD, PhD,&nbsp;Mauro Saieg MD, PhD, MIAC,&nbsp;Spasenija Savic Prince MD,&nbsp;Momin T. Siddiqui MD,&nbsp;Tajana Stoos-Veic MD, PhD,&nbsp;Margareta Strojan Fležar MD, PhD, MIAC,&nbsp;Dinka Sundov MD, PhD,&nbsp;Paul VanderLaan MD, PhD,&nbsp;Danijela Vrdoljak-Mozetič MD, PhD,&nbsp;Pio Zeppa MD, PhD,&nbsp;Giancarlo Troncone MD, PhD,&nbsp;Elena Vigliar MD, PhD","doi":"10.1002/cncy.70003","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The aim of this project is to assess interobserver agreement for programmed death-ligand 1 (PD-L1) scoring on of non–small cell lung cancer (NSCLC) on cytological specimens in a large-scale multicenter study, by exploiting the cell block-derived tissue microarray (cbTMA) approach.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 65 cell blocks (CB) diagnosed as NSCLC were retrospectively collected and selected for TMA preparation. Hematoxylin–eosin and PD-L1 stained slides were digitized and uploaded on a free web sharing platform. Participants were asked to provide PD-L1 assessment by using the clinically relevant cutoff of tumor proportion score (TPS) (&lt;1%; 1%–49%; &gt;50%). Interobserver agreement was calculated using Fleiss’s κ.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 65 CBs, 11 were deemed not suitable; therefore, an overall number of 54 cores were used for the preparation of four TMAs. A total of 1674 evaluations were provided by 31 cytopathologists from 21 different institutions in nine countries. The statistical analysis showed a moderate overall agreement (κ = 0.49). The highest agreement was achieved in the TPS &gt;50% category (κ = 0.57); moderate agreement was observed in TPS &lt;1% category (κ = 0.51) and the lowest κ value was obtained for TPS 1%–49% category (k = 0.32).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The overall moderate agreement observed showed that there is still room for improvement in inter-pathologist agreement for PD-L1 evaluation on cytological samples, highlighting the need for standardization in sample preparation, focused training in PD-L1 evaluation on cytological material, and the integration of machine learning tools to improve interobserver consistency.</p>\n </section>\n </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"133 3","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.70003","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncy.70003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The aim of this project is to assess interobserver agreement for programmed death-ligand 1 (PD-L1) scoring on of non–small cell lung cancer (NSCLC) on cytological specimens in a large-scale multicenter study, by exploiting the cell block-derived tissue microarray (cbTMA) approach.

Methods

A total of 65 cell blocks (CB) diagnosed as NSCLC were retrospectively collected and selected for TMA preparation. Hematoxylin–eosin and PD-L1 stained slides were digitized and uploaded on a free web sharing platform. Participants were asked to provide PD-L1 assessment by using the clinically relevant cutoff of tumor proportion score (TPS) (<1%; 1%–49%; >50%). Interobserver agreement was calculated using Fleiss’s κ.

Results

Of 65 CBs, 11 were deemed not suitable; therefore, an overall number of 54 cores were used for the preparation of four TMAs. A total of 1674 evaluations were provided by 31 cytopathologists from 21 different institutions in nine countries. The statistical analysis showed a moderate overall agreement (κ = 0.49). The highest agreement was achieved in the TPS >50% category (κ = 0.57); moderate agreement was observed in TPS <1% category (κ = 0.51) and the lowest κ value was obtained for TPS 1%–49% category (k = 0.32).

Conclusions

The overall moderate agreement observed showed that there is still room for improvement in inter-pathologist agreement for PD-L1 evaluation on cytological samples, highlighting the need for standardization in sample preparation, focused training in PD-L1 evaluation on cytological material, and the integration of machine learning tools to improve interobserver consistency.

Abstract Image

细胞学样本Pd-l1评价的观察者间协议- sampling项目:一项多机构的国际研究
本项目的目的是通过利用细胞块衍生组织微阵列(cbTMA)方法,在一项大规模的多中心研究中,评估非小细胞肺癌(NSCLC)细胞学标本上程序性死亡配体1 (PD-L1)评分的观察者间一致性。方法回顾性收集确诊为非小细胞肺癌的细胞块(CB) 65例,进行TMA制备。苏木精-伊红和PD-L1染色切片数字化并上传到免费的网络共享平台。参与者被要求通过使用肿瘤比例评分(TPS)的临床相关截止点(<1%;1% - -49%;在50%)。使用Fleiss’s κ计算观察者间一致性。结果65例CBs中,11例认为不适宜;因此,总共使用了54个核来制备4个tma。来自9个国家21个不同机构的31名细胞病理学家共进行了1674次评估。统计学分析显示总体一致性中等(κ = 0.49)。在TPS >;50%类别中一致性最高(κ = 0.57);TPS <;1%组的κ值为0.51,TPS 1% ~ 49%组的κ值最低(k = 0.32)。观察到的总体中等一致性表明,病理学家之间对细胞学样品PD-L1评估的一致性仍有改进的空间,突出了样品制备标准化的必要性,细胞学材料PD-L1评估的重点培训,以及整合机器学习工具以提高观察者之间的一致性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Cytopathology
Cancer Cytopathology 医学-病理学
CiteScore
7.00
自引率
17.60%
发文量
130
审稿时长
1 months
期刊介绍: Cancer Cytopathology provides a unique forum for interaction and dissemination of original research and educational information relevant to the practice of cytopathology and its related oncologic disciplines. The journal strives to have a positive effect on cancer prevention, early detection, diagnosis, and cure by the publication of high-quality content. The mission of Cancer Cytopathology is to present and inform readers of new applications, technological advances, cutting-edge research, novel applications of molecular techniques, and relevant review articles related to cytopathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信